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Yu-Huei Huang1,2, Chang-Fu Kuo2,3, Yi-Hua Chen4 and Ya-Wen Yang5,6
Pemphigus is a potentially life-threatening autoimmune blistering disease. However, little is known about the
all-cause and cause-specific mortality among patients with pemphigus compared with the general population.
The incidence of pemphigus in Taiwan has not been described previously. The objective of this study was to
estimate the incidence of pemphigus in Taiwan and to investigate the overall mortality, causes of death, and
cause-specific mortality in a nationwide population-based cohort of pemphigus patients. The study cohort
included 853 patients newly diagnosed with pemphigus between 2002 and 2009 in the National Health Insurance
Research Database. Survival status, date of death, and cause of death were ascertained by linking the study
cohort with the National Register of Deaths Database of Taiwan. All-cause and cause-specific standardized
mortality ratios (SMRs) were estimated. The incidence of pemphigus in Taiwan was 4.7 (95% confidence interval
(CI), 3.2–6.2) per million per year. Overall, 88 deaths were observed during a mean follow-up period of 3.8 years,
which was more than two times the number expected (SMR, 2.36; 95% confidence interval, 1.92–2.91). In the
analysis of causes of death, the SMRs for death due to pneumonia (3.64; 95% CI, 1.30–10.21), septicemia (11.57;
95% CI, 2.95–45.34), cardiovascular disease (2.69; 95% CI, 1.18–6.12), and peptic ulcer disease (8.44; 95% CI,
1.22–58.21) were significantly higher than expected. We concluded that the incidence of pemphigus is not low in
Taiwan, and the overall mortality among pemphigus patients is two times greater than that of the general
population. In particular, patients with pemphigus have higher risk of mortality from systemic and respiratory
tract infections, cardiovascular disease, and peptic ulcer disease.
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INTRODUCTION
Pemphigus is a rare, chronic autoimmune blistering disease
of skin and mucous membranes. There are two major types of
pemphigus: pemphigus vulgaris and pemphigus foliaceus.
The etiopathogenesis of pemphigus is characterized by
acantholysis and intraepidermal blister formation, resulting
from IgG autoantibodies directed against desmoglein 3
(pemphigus vulgaris) and/or desmoglein 1 (pemphigus
foliaceus), two transmembrane glycoproteins of desmosomes
(Stanley, 2008). The incidence of pemghigus varies by
geographic area and ethnic groups. It has been reported that
the incidence of pemphigus vulgaris ranges from 0.76 per
million population per year in Finland to 16 per million per
year in Israel, and the incidence of pemphigus foliaceus
varies between 0.5 and 1.0 per million per year in Western
Europe and 6.7 per million per year in Tunisia (Bastuji-Garin
et al., 1995; Wohl and Brenner, 2003; Stanley, 2008).
Systemic corticosteroids and immunosuppressive therapy
are the mainstay treatments for pemphigus. The prognosis for
patients with pemphigus has greatly improved since the
introduction of corticosteroid therapy; nevertheless, pemphi-
gus remains a potentially life-threatening disease (Stanley,
2008). One study of 159 patients with pemphigus vulgaris
admitted to the hospital from 1980 to 1998 documented a
mortality rate of 8.8 % (14 patients) during hospital treatment;
the main causes of death were cardiopulmonary failure and
sepsis (Ljubojevic et al., 2002). Another study of 148 patients
with pemphigus revealed that 4.8% of patients died in a
mean follow-up period of 25 months, most commonly due to
septicemia (Uzun et al., 2006). Although previous hospital-
based research has shown a higher risk of death among
patients with pemphigus, little is known about mortality from
pemphigus in a large representative cohort compared with
the general population of the same age and gender. A recent
population-based study conducted in the United Kingdom
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found that the age- and gender-adjusted mortality rate among
138 patients with pemphigus vulgaris was three times higher
than that of controls. However, underlying causes of death
were not examined in that study (Langan et al., 2008).
Therefore, the objectives of this study were to investigate
the mortality of patients with pemphigus, to describe causes
of death, and to determine cause-specific mortality for a
nationwide cohort of patients with pemphigus. In addition,
we also sought to estimate the incidence of pemphigus in
Taiwan because data on the epidemiology of this uncommon
autoimmune blistering disease is limited in this country.
RESULTS
Characteristics of the study cohort
Our study cohort consists of 853 patients with pemphigus
who were first diagnosed between 1 January 2002 and 31
December 2009, including 366 (42.9%) male and 487
(57.1%) female patients. The mean age of onset of pemphigus
was 52.5±15.9 years (median, 51 years), and the mean
length of follow-up was 3.8±2.1 years (median, 3.9 years).
A total of 88 patients (10.3%) died during the study period,
of whom 54 were male and 34 were female (Table 1).
Incidence
The average incidence rate of pemphigus in Taiwan during the
8-year study period was 4.7 (95% confidence interval (CI),
3.2–6.2) per million per year (Table 1). The incidence was
higher in women, at a rate of 5.4 (95% CI, 3.6–7.3) per million
per year, than in men, at a rate of 4.0 (95% CI, 2.7–5.2) per
million per year (Po0.001). Figure 1 displays the incidence
rates stratified by gender and age groups (o40, 40–60, X60).
People aged 60 years and older had the highest risk of
developing pemphigus, with an incidence rate of 11.9 (95% CI,
6.2–17.5) and 10.5 (95% CI, 6.7–14.3) per million per year for
men and women, respectively. On the other hand, the lowest
incidence of pemphigus was seen in patients less than 40 years
of age, with a rate of 1.4 (95% CI, 0.7–2.0) and 2.0 (1.1–2.9) per
million per year for men and women, respectively.
Mortality
Of the 88 cases who died during the study period, about half
(45 cases, 51.1%) died within 1 year of being diagnosed with
pemphigus. There was no statistically significant difference in
the mean age of onset of pemphigus between those who
survived less than 1 year and those who survived at least 1
year and died later (70.9 vs. 68.0 years, P¼0.34).
The survival rates for patients with pemphigus were
strikingly lower when compared with the general population.
Kaplan–Meier survival curves for both male and female
pemphigus cohorts were lower than those expected in the
age-matched male and female general populations (Figure 2).
Overall, patients with pemphigus experienced 2.36 times the
expected number of deaths (SMR, 2.36; 95% CI, 1.92–2.91).
In gender-specific analysis, the SMRs for those with
pemphigus were significantly increased both for men (SMR,
2.21; 95% CI, 1.70–2.89) and women (SMR, 2.65; 95% CI,
1.90–3.71). Table 2 shows the results of calculated SMRs
Table 1. Characteristics of 853 patients with pemphigus
vulgaris first diagnosed between 2002 and 2009
Total Male Female
No. 853 366 487
Age at incidence, years
Mean (SD) 52.5 (15.9) 54.5 (16.8) 51.0 (15.1)
Median (range) 51 (13–95) 53.5 (13–90) 50 (17–95)
Length of follow-up, years
Mean (SD) 3.8 (2.1) 3.6 (2.1) 3.9 (2.0)
Median (range) 3.9 (0–7.3) 3.7 (0–7.3) 4.1 (0–7.3)
Incidence rate (95% CI)
Case per million
persons per year
4.7 (3.2–6.2) 4.0 (2.7–5.2) 5.4 (3.6–7.3)
No. of deaths
during follow-up
88 54 34
Abbreviation: CI, confidence interval.
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Figure 1. Incidence of pemphigus in Taiwan between 1 January 2002 and
31 December 2009.
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Figure 2. Survival among patients first diagnosed with pemphigus between 1
January 2002 and 31 December 2009, compared with expected survival.
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further stratified by age group at diagnosis. Most of the deaths
and the highest mortality rates (95.9 and 56.3 per 1,000
person-years for men and women, respectively) were
observed among patients with pemphigus onset at 60 years
of age or later. When compared with the expected deaths in
the general population, the highest SMRs were found in
patients with pemphigus onset who were less than 40 years of
age, with a value of 4.83 (95% CI, 1.56–14.97) for men and
6.28 (95% CI, 1.57–25.10) for women.
Specific causes of death
Table 3 illustrates deaths in patients with pemphigus during
the study period by cause. Pemphigus was the most commonly
certified cause of death (n¼ 18, 20.4%). Other than pemphigus,
the major causes of death were infectious diseases (n¼16,
18.4%), malignancy (n¼ 17, 19.3%), and cardiovascular
diseases (n¼ 11, 12.5%). When compared with the general
population, patients with pemphigus showed a statistically
significant increased likelihood of death resulting from
pneumonia (SMR, 3.64; 95% CI, 1.30–10.21), septicemia
(SMR, 11.57; 95% CI, 2.95–45.34), cardiovascular disease (SMR,
2.69; 95% CI, 1.18–6.12), and peptic ulcer disease (SMR, 8.44;
95% CI, 1.22–58.21; Table 4).
DISCUSSION
This nationwide population-based study demonstrated that,
although lower than that in Israel (Wohl and Brenner, 2003),
the incidence of pemphigus in Taiwan (4.7 cases per million
per year) was comparable to that in Bulgaria (4.7 per million
per year; Uzun et al., 2006), South India (4.4 per million per
Table 2. Observed and expected deaths and standard
mortality ratios in patients with pemphigus stratified
by gender and age at incidence
Person-
years
Observed deaths
(rate, per 1,000)1
Expected
deaths SMR (95% CI)
Overall 3,221.6 88 (27.3) 37.2 2.36 (1.92–2.91)
Males 1,330.7 54 (40.6) 24.4 2.21 (1.70–2.89)
Age at
incidence,
years
o40 298.4 3 (10.1) 0.6 4.83 (1.56–14.97)
40–59 562.9 6 (10.7) 3.9 1.53 (0.69–3.41)
X60 469.5 45 (95.9) 19.9 2.27 (1.69–3.03)
Females 1,890.9 34 (18.0) 12.8 2.65 (1.90–3.71)
Age at
incidence,
years
o40 430.1 2 (4.7) 0.3 6.28 (1.57–25.10)
40–59 1,034.4 8 (7.7) 3.0 2.65 (1.33–5.30)
X60 426.5 24 (56.3) 9.5 2.53 (1.70–3.78)
Abbreviations: CI, confidence interval; SMR, standardized mortality ratio.
1Mortality rate per 1,000 person-years.
Table 3. Distribution of causes of death in patients
with pemphigus in Taiwan, January 2002–December
2009
Cause of death n %
Infectious diseases 16 18.2
Pneumonia 7 8.0
Urinary tract infection 2 2.3
Skin and soft tissue 1 1.1
Central nervous system 1 1.1
Pulmonary tuberculosis 1 1.1
Septicemia 4 4.5
Malignancy 17 19.3
Carcinoma, liver 3 3.4
Carcinoma, genitourinary tract 2 2.3
Carcinoma, prostate 2 2.3
Carcinoma, stomach 2 2.3
Carcinoma, uterine cervix 2 2.3
Carcinoma, lung 2 2.3
Carcinoma, gallbladder 1 1.1
Carcinoma, nasopharynx 1 1.1
Malignant thymoma 1 1.1
Retroperitoneal malignancy 1 1.1
Cardiovascular diseases 11 12.5
Ischemic heart disease 3 3.4
Hypertensive heart disease 4 4.5
Aortic aneurysm 1 1.1
Congestive cardiac failure 3 3.4
Gastrointestinal diseases 5 5.7
Peptic ulcer disease 2 2.3
Gastrointestinal obstruction 1 1.1
Colitis 1 1.1
Other 1 1.1
Metabolic disease 5 5.7
Diabetes mellitus 4 4.5
Electrolyte imbalance 1 1.1
Neurological diseases 4 4.5
Cerebrovascular disease 3 3.4
Parkinson’s disease 1 1.1
Chronic renal disease 3 3.4
Chronic obstructive pulmonary disease 1 1.1
Pemphigus vulgaris 18 20.4
Trauma 1 1.1
Ill-defined and unknown cause 7 8.0
Total 88 100.0
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year; Kumar, 2008), Iran (6.7 per million per year;
Salmanpour et al., 2006), and the United Kingdom (6.8 per
million per year; Langan et al., 2008), and is higher than that
in Finland (0.76 per million per year), France (0.17 per
million per year), and Germany (0.98 per million per year;
Uzun et al., 2006). The higher incidence observed in women
than in men in our study is consistent with female
predominance of pemphigus in the literature (Uzun et al.,
2006; Langan et al., 2008). There was a rise in the incidence
of pemphigus with increasing age, especially in men. The
mean age of onset of pemphigus in Taiwan is not as early as
that in some Middle Eastern and Mediterranean countries,
including Iran (38 years; Salmanpour et al., 2006), Kuwait
(35.8 years; Alsaleh et al., 1999), and Tunisia (36.7 years;
Bastuji-Garin et al., 1995), but is similar to the age of onset in
Bulgaria (54.3 and 56.9 years for men and women,
respectively) and Greece (59.6 and 55.8 years for men and
women, respectively; Tsankov et al., 2000; Michailidou
et al., 2007).
Our study showed that survival in patients diagnosed with
pemphigus was significantly lower than that expected in the
general population. Overall, patients with pemphigus had a
2.36-fold increase in mortality compared with the general
population. Pemphigus is an autoimmune blistering disease
associated with a relatively high mortality rate after diagnosis,
ranging in the literature from 5 to 30% during various lengths
of follow-up. For example, Uzun et al. (2006) reported a
mortality rate of 4.8% among 148 patients with pemphigus in
Turkey during a mean follow-up period of 25 months.
Shamsadini et al. (2006) demonstrated in a study from Iran
that mortality rates were 7.3, 13.2, and 39.5% at 2, 6, and 8
years, respectively, following diagnosis with pemphigus. One
study conducted in a medical center in Northern Taiwan
observed 15 deaths among 58 pemphigus patients (25.9%)
during a mean follow-up period of 9.2 years.(Su et al., 2005)
However, prior studies mainly used small hospital-based
samples, and were unable to estimate the risk of mortality
among patients with pemphigus relative to the general
population.
A recent population-based cohort study by Langan et al.
(2008) compared 138 patients with pemphigus vulgaris to
551 randomly selected age- and gender-matched controls in
the United Kingdom and revealed that the risk of death for
patients with pemphigus vulgaris was 3.3 times higher than
that for controls. Their results were generally parallel with our
SMRs, although slightly higher. Our data demonstrated that
patients with pemphigus onset after the age of 60 years had
much higher mortality rates than those whose disease onset
was before 60 years age, both among men and women. This
finding is in accordance with previous reports that elderly
pemphigus patients have worse prognoses and poorer
survival rates compared with younger patients (Wolf et al.,
1995; Shamsadini et al., 2006). Nevertheless, the SMR was
greatest for patients with pemphigus onset before 40 years of
age, because the background mortality in this age group in
the general population is very low.
In the analysis of specific causes of death, about 20% of
the patients were certified as having died from pemphigus,
which is consistent with the fact that pemphigus is an
intractable and devastating disease. Although malignancy
was one of the major causes of death, its SMR was not
significantly higher than expected. The SMRs for infectious
diseases, mainly pneumonia and septicemia,cardiovascular
disease, and peptic ulcer disease, were all significantly higher
than expected. It has been reported in case series or selective
hospital-based cohorts that side effects from prolonged
corticosteroid and adjuvant immunosuppressive therapy,
including systemic infection, pneumonia, diabetes, arterial
hypertension, cardiorespiratory diseases, and peptic ulcera-
tion, were the most common complications and events
leading to death seen in patients with pemphigus (Savin,
1979; Ljubojevic et al., 2002). Our study, which uses a large
national cohort of patients with pemphigus, contributes an
epidemiologic figure of all-cause and cause-specific mortality
for pemphigus compared with the general population.
Our study has some limitations. First, although pemphigus
identified from the catastrophic illness certificates of the
National Health Insurance Research Database (NHIRD) is
highly reliable and valid because of the strict review needed
to attain catastrophic illness status in Taiwan, information on
the type of pemphigus was not available in the database.
Therefore, we were unable to divide our study cohort into
different types of pemphigus, e.g., pemphigus vulgaris and
pemphigus foliaceus, and to examine their mortality,
respectively. Second, although most patients will apply for
catastrophic illness certificate at the diagnosis of pemphigus
in order to waive their co-payments, we cannot be certain
that we have included all patients with incident pemphigus in
our study. Third, instead of reviewing medical records,
causes of death were ascertained from a death certificate
database that often recorded ill-defined and unknown causes
of death (7 of 88 deaths in this study), resulting in the
possibility of underestimating cause-specific mortality and
the corresponding SMRs. Finally, data about clinical severity
Table 4. Observed and expected deaths and standard
mortality ratios of specific causes of death
Cause of death
Observed
deaths
Expected
deaths SMR (95% CI)1
Pneumonia 7 1.9 3.64 (1.30–10.21)2
Septicemia 4 0.4 11.57 (2.95–45.34)2
Malignancy 17 11.3 1.50 (0.78–2.92)
Cardiovascular disease 11 4.1 2.69 (1.18–6.12)2
Diabetes mellitus 4 2.7 1.50 (0.38–5.90)
Cerebrovascular disease 3 3.4 0.88 (0.18–4.24)
Chronic renal disease 3 1.3 2.30 (0.47–11.11)
Peptic ulcer disease 2 0.2 8.44 (1.22–58.21)2
Abbreviations: CI, confidence interval; SMR, standardized mortality ratio.
1Bonferroni-adjusted 95% CI, i.e., Bonferroni’s adjustment was made for
multiple comparisons with an overall significance level at 0.05.
2Causes of death for which SMRs were significantly increased compared
with that expected for the general population.
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of pemphigus and corticosteroids and/or immunosuppressive
agents given to the patients could not be obtained for the
study. Thus, we could not evaluate how the use of cortico-
steroids and/or immunosuppressive agents may have affected
the mortality and causes of mortality in patients with pemphigus.
Future studies including details of therapy are needed to
elucidate this issue.
In conclusion, the findings of this nationwide population-
based study indicate that the incidence of pemphigus is not
low in Taiwan, and the risk of all-cause mortality among
those with pemphigus is two times greater than that expected
in the general population. In particular, patients with pemphigus
in Taiwan have a higher risk of mortality from systemic and
respiratory tract infections, cardiovascular disease, and peptic
ulcer disease compared with the general population.
MATERIALS AND METHODS
Data sources
This is a population-based cohort study using the NHIRD, released
by the Taiwan National Health Research Institute. The National
Health Insurance program is a universal health-care system in
Taiwan that was established in 1995. As of 2007, up to 98% of
Taiwan’s entire population (about 22.60 million) was enrolled in
this program. The NHIRD contains all the medical claims data,
including claims for inpatient care and ambulatory care, for all
beneficiaries of the program. This database is generally accurate
and has been the source of more than 300 studies published in
peer-reviewed journals (Chen et al., 2011).
The Catastrophic Illness Dataset is a data subset of the NHIRD.
Under the National Health Insurance program, patients with certain
major diseases can apply for a catastrophic illness certificate and
are exempt from the usual co-payments. Pemphigus is included
in the 30 categories of illness and injury that are recognized
as catastrophic illness by the Department of Health in Taiwan
(Bureau of National Health Insurance, http://www.nhi.gov.tw/
english/index.aspx). Typical clinical presentation, as well as
histopathological and immunological evidence of pemphigus, is
required to apply for a catastrophic illness certificate for pemphigus.
Although we believe that most patients will apply for this certificate,
it is not possible for us to ascertain how many patients with
pemphigus did not apply for this certificate.
Study population
The study population comprised all patients who received a new
diagnosis of pemphigus between 1 January 2002 and 31 December
2009, identified through the catastrophic illness registry. The date
of pemphigus onset was defined as the date of application for a
catastrophic illness certificate. Patients who had been diagnosed
with malignancy before the onset of pemphigus were not included
in the study cohort.
Death ascertainment
Survival status, date of death, and cause of death among patients
with pemphigus was ascertained by linking the study cohort with the
National Register of Deaths Database of Taiwan. The underlying
cause of death on the death certificate was coded according to the
International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9 CM) in computerized data files. All patients
were followed up from the onset of pemphigus until 31 December
2009, exiting the study earlier whenever they died during the
observation period.
Statistical analysis
Data for the Taiwan population provided by the Ministry of the
Interior, Department of Statistics (http://www.moi.gov.tw/stat/english
/index.asp), Taiwan, were used to calculate the overall mean
incidence and the incidence of pemphigus in Taiwan from 2002 to
2009, stratified by sex and age group (o40, 40–60, X60). The 95%
CI of the incidence rate was estimated by the Poisson distribution
model.
Observed survival curve from the onset of pemphigus was
estimated using the Kaplan–Meier method. The expected survival
curve of the study cohort was computed according to Hakulinen’s
method (Hakulinen, 1982) using gender-, age- (1-year classes), and
calendar year-specific (1-year classes) mortality rates for the
population of Taiwan (Ministry of the Interior, Department of
Statistics, http://www.moi.gov.tw/stat/english/life.asp). To compare
the observed and expected survival rates, we calculated standar-
dized mortality ratios (SMRs), the ratio of the observed to the
expected number of deaths, with 95% Poisson confidence intervals.
The expected number of deaths was calculated by multiplying
person-years of each gender-, age (1-year classes)-, and calendar
year-specific stratum of the study cohort by the corresponding
mortality rate of Taiwan population and then summed up across all
strata. Cause-specific SMRs were also calculated based on gender-,
age (5-year classes)- and calendar year-specific mortality rates for
specific causes of death (if available) for the Taiwan population
(Department of Health, Executive Yuan, R.O.C.). Because multiple
comparisons were being made, the Bonferroni method was
performed to ensure that the overall significance level does not
exceed 0.05. Correspondingly, Bonferroni-adjusted confidence
intervals were constructed for each cause-specific SMRs with an
overall 95% confidence interval (Kutner et al., 2005). All analyses
were performed using STATA statistical software version 8.2
(StataCorp, College Station, TX).
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